Literature DB >> 4115705

The human rosette-forming cell as a marker of a population of thymus-derived cells.

J Wybran, M C Carr, H H Fudenberg.   

Abstract

Sheep red blood cells can surround, in vitro, some human peripheral blood lymphocytes in a formation called a rosette. The number of rosetteforming cells (RFC) in 50 normal persons had a wide range (4-40%). The organs of 13 human fetuses (11-19 wk conceptional age) were examined for the presence of RFC. The thymus possessed the highest percentage of RFC, the maximum being 65% of total thymocytes in two 15-16 wk fetal specimens. Blood RFC were always present and their number slightly increased in the oldest fetuses. The bone-marrow showed 0-8% in the six fetuses studied. RFC were found in the spleen around the 13th wk and in the liver around the 17th wk of gestation. These observations lead to the hypothesis that human blood RFC may be chiefly thymic derived. Studies of patients with immunological disorders support this hypothesis: one patient with Nezelof syndrome had no blood RFC and four patients with Wiskott-Aldrich syndrome had a low number of blood RFC (1 and 1.5%). Patients with acquired hypogammaglobulinemia showed a normal percentage of RFC. With the fetal thymocytes, the percentage of inhibition with anti-mu serum increased with the fetal age to become complete in the oldest fetuses studied. Incubation of the oldest fetal thymocytes or the blood lymphocytes with anti-gamma serum of anti-mu serum completely inhibited the rosette formation. These results suggest that mu-chain determinants are present on human fetal thymocytes and blood RFC. The significance of the presence of gamma-chain determinants on these cells is unclear.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4115705      PMCID: PMC332950          DOI: 10.1172/JCI107069

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  31 in total

1.  Chromic chloride: a coupling reagent for passive hemagglutination reactions.

Authors:  E R Gold; H H Fudenberg
Journal:  J Immunol       Date:  1967-11       Impact factor: 5.422

2.  Rapid preparation of lymphocytes for tissue-typing.

Authors:  R Harris; E O Ukaejiofo
Journal:  Lancet       Date:  1969-08-09       Impact factor: 79.321

3.  Anti-theta antibodies for detecting thymus-dependent lymphocytes in the immune response of mice to SRBC.

Authors:  M Schlesinger
Journal:  Nature       Date:  1970-06-27       Impact factor: 49.962

4.  Pluripotential stem cells in mouse embryo liver.

Authors:  R B Taylor
Journal:  Br J Exp Pathol       Date:  1965-08

5.  Theta isoantigen as a marker of thymus-derived lymphocytes in mice.

Authors:  M Raff
Journal:  Nature       Date:  1969-10-25       Impact factor: 49.962

6.  Correlation of lymphocyte transformation and morphology in the human fetal thymus.

Authors:  M Papiernik
Journal:  Blood       Date:  1970-10       Impact factor: 22.113

7.  [Recognition of antigen in vivo by cells forming spontaneous rosettes].

Authors:  J F Bach; M Dardenne; J Y Muller
Journal:  C R Acad Hebd Seances Acad Sci D       Date:  1970-04-27

8.  [Significance of the rosette phenomenon in non-immunized mice].

Authors:  J F Bach; M Dardenne
Journal:  C R Acad Hebd Seances Acad Sci D       Date:  1969-08-11

9.  In vitro rosette inhibition by antihuman antilymphocyte serum. Correlation with skin graft prolongation in subhuman primates.

Authors:  J F Bach; J Dormont; M Dardenne; H Balner
Journal:  Transplantation       Date:  1969-09       Impact factor: 4.939

10.  Development of gamma G, gamma A, gamma M, beta IC-beta IA, C 1 esterase inhibitor, ceruloplasmin, transferrin, hemopexin, haptoglobin, fibrinogen, plasminogen, alpha 1-antitrypsin, orosomucoid, beta-lipoprotein, alpha 2-macroglobulin, and prealbumin in the human conceptus.

Authors:  D Gitlin; A Biasucci
Journal:  J Clin Invest       Date:  1969-08       Impact factor: 14.808

View more
  111 in total

1.  Comparative, immunological studies on lymphangiectasia of the small intestine revealed in protein losing gastroenteropathy and Behçet's disease.

Authors:  M Tsuchiya; T Hibi; Y Mizuno; A Ono; A Morita
Journal:  Gastroenterol Jpn       Date:  1976

2.  Clonal proliferation of PHA-stimulated human lymphocytes in soft agar culture.

Authors:  L A Rozenszajn; D Shoham; I Kalechman
Journal:  Immunology       Date:  1975-12       Impact factor: 7.397

3.  Role of thymus grafting in treatment of immunodeficiency.

Authors:  J G Watson; K Hugh-Jones
Journal:  Proc R Soc Med       Date:  1975-09

4.  T and B lymphocytes in humans. A review.

Authors:  J H Kersey; J Gajl-Peczalska
Journal:  Am J Pathol       Date:  1975-11       Impact factor: 4.307

5.  Morphological, immunological and immunocytochemical identification of lymphocytes extracted from cutaneous infiltrates.

Authors:  A L Claudy; D Schmitt; J Viac; A Alario; M J Staquet; J Thivolet
Journal:  Clin Exp Immunol       Date:  1976-01       Impact factor: 4.330

6.  Correlations among cutaneous reactivity to DNCB, PHA-induced lymphocyte blastogenesis and peripheral blood E rosettes.

Authors:  W J Catalona; J L Tarpley; C Potvin; P B Chretien
Journal:  Clin Exp Immunol       Date:  1975-02       Impact factor: 4.330

7.  The immune status of uraemic children/adolescents with chronic renal failure and renal replacement therapy.

Authors:  R Drachman; M Schlesinger; H Shapira; A Drukker
Journal:  Pediatr Nephrol       Date:  1989-07       Impact factor: 3.714

8.  Characterization of non-Hodgkin's lymphomas using multiple cell markers. Immunologic, morphologic, and cytochemical studies of 72 cases.

Authors:  G S Pinkus; J W Said
Journal:  Am J Pathol       Date:  1979-02       Impact factor: 4.307

9.  Theophylline modulation of E-rosette formation: an indicator of T-cell maturation.

Authors:  S Limatibul; A Shore; H M Dosch; E W Gelfand
Journal:  Clin Exp Immunol       Date:  1978-09       Impact factor: 4.330

10.  Studies of the human lymphocyte-mouse erythrocyte bond.

Authors:  P D Zalewski; I J Forbes
Journal:  Clin Exp Immunol       Date:  1979-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.